BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Dr. Kleinhaus of Pluristem Therapeutics on Immune-Advantaged Placental-Derived PLX-Cells
Placental-derived PLX Cells

Dr. Kleinhaus of Pluristem Therapeutics on Immune-Advantaged Placental-Derived PLX-Cells

May 30, 2017 By Cade Hildreth (CEO) Leave a Comment

Pluristem TherapeuticsPluristem Therapeutics is a clinical-stage biotherapy company using placental cells and an advanced 3D manufacturing platform to develop cell therapies for conditions that include inflammation, ischemia, muscle trauma, hematological disorders, or exposure to radiation. Their two lead cell products are entering late-stage clinical trials. Based in Haifa, Israel, Pluristem’s propriety bioreactor technology provides full-scale cell manufacturing capabilities that allow it to expand trillions of cells and create a commercial-grade product.

Discover class-defining bioproduction tools.

In the video below, Karine Kleinhaus, MD, MPH, Divisional Vice President, North America at Pluristem Therapeutics, discusses the company’s 3D manufacturing technology, as well as the strategic advantages of its placental-derived PLX cells, which are “off-the-shelf” products that do not need genetic or tissue matching prior to administration and could be delivered in almost any clinical setting. She also discusses the company’s current PLX-PAD clinical trials and recent non-human primate study of PLX-R18 in Acute Radiation Syndrome (ARS).

To learn more, watch Pluristem Therapeutics’ Cell and Gene Investor Day presentation with Dr. Karine Kleinhaus and Edward Tenthoff, Managing Director and Senior Research Analyst at Piper Jaffray.

bitbio

For more information, view our recent interview with Yaky Yanay, President and Co-CEO of Pluristem Therapeutics.

 

Rate this post

Filed Under: Stem Cells Tagged With: placental, Pluristem Therapeutics, PLX-R18

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

Cord Blood Market Segmentation

Cord Blood Market Segmentation – Biobanking, HSCT, Cellular Therapy, Genetic Manipulation, & Research Tools

CAR-T Companies

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.